Cytomos reports that it is showcasing its flagship cell analytic intelligence platform AuraCyt®, together with its novel Celledonia® benchtop technology, designed to enhance predictive cell analytics. Current challenges in the bioprocessing sector include slow, label-dependent analytical methods that hinder scalability and offer limited predictive insights, according to Cytomos.
The AuraCyt platform measures intrinsic cell physics to generate AI-ready digital fingerprints that elucidate the multi-dimensional state and behavior of cells. This benchtop cell analytics intelligence system integrates the compact Celledonia analyzer with the AuraCyt modules, transforming complex cellular data into actionable insights. A Cytomos spokesperson emphasizes that this label-free, single-cell analysis system predicts future productivity, stability, and manufacturability.
This capability enables earlier insights and real-time decision-making, thereby lowering risk, optimizing processes, and improving product consistency. The operation reportedly delivers significant value across various applications, such as reducing CLD timelines by up to 40%, saving up to 65% of resources in lentivirus batch production, and decreasing CAR T process time by up to 30%, according to Cytomos’ executive chair, Alan Raymond.
The company is showcasing this technology at its pod in BIO Business Forum Zone D (Exhibit Hall 2221 UK Pavilion), from June 22-25, 2026.
Use the database as your supply chain compass →
